View source for 6hkr


==Human Cellular Retinoic Acid Binding Protein II (CRABPII) with bound synthetic retinoid DC271.==
<StructureSection load='6hkr' size='340' side='right' caption='[[6hkr]], [[Resolution|resolution]] 1.50&Aring;' scene=''>
== Structural highlights ==
<table><tr><td colspan='2'>[[6hkr]] is a 1 chain structure with sequence from [http://en.wikipedia.org/wiki/Human Human]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6HKR OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=6HKR FirstGlance]. <br>
</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=EDO:1,2-ETHANEDIOL'>EDO</scene>, <scene name='pdbligand=G9Q:4-[2-(4,4-dimethyl-1-propan-2-yl-2,3-dihydroquinolin-6-yl)ethynyl]benzoic+acid'>G9Q</scene>, <scene name='pdbligand=GOL:GLYCEROL'>GOL</scene>, <scene name='pdbligand=PG4:TETRAETHYLENE+GLYCOL'>PG4</scene></td></tr>
<tr id='gene'><td class="sblockLbl"><b>[[Gene|Gene:]]</b></td><td class="sblockDat">CRABP2 ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=9606 HUMAN])</td></tr>
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=6hkr FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6hkr OCA], [http://pdbe.org/6hkr PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=6hkr RCSB], [http://www.ebi.ac.uk/pdbsum/6hkr PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=6hkr ProSAT]</span></td></tr>
</table>
== Function ==
[[http://www.uniprot.org/uniprot/RABP2_HUMAN RABP2_HUMAN]] Transports retinoic acid to the nucleus. Regulates the access of retinoic acid to the nuclear retinoic acid receptors. 
<div style="background-color:#fffaf0;">
== Publication Abstract from PubMed ==
Vitamin A derived retinoid compounds have multiple, powerful roles in the cellular growth and development cycle and, as a result, have attracted significant attention from both academic and pharmaceutical research in developing and characterizing synthetic retinoid analogues. Simplifying the hit development workflow for retinoid signaling will improve options available for tackling related pathologies, including tumor growth and neurodegeneration. Here, we present a novel assay that employs an intrinsically fluorescent synthetic retinoid, DC271, which allows direct measurement of the binding of nonlabeled compounds to relevant proteins. The method allows for straightforward initial measurement of binding using existing compound libraries and is followed by calculation of binding constants using a dilution series of plausible hits. The ease of use, high throughput format, and measurement of both qualitative and quantitative binding offer a new direction for retinoid-related pharmacological development.

Novel Fluorescence Competition Assay for Retinoic Acid Binding Proteins.,Tomlinson CWE, Chisholm DR, Valentine R, Whiting A, Pohl E ACS Med Chem Lett. 2018 Nov 9;9(12):1297-1300. doi:, 10.1021/acsmedchemlett.8b00420. eCollection 2018 Dec 13. PMID:30613343<ref>PMID:30613343</ref>

From MEDLINE&reg;/PubMed&reg;, a database of the U.S. National Library of Medicine.<br>
</div>
<div class="pdbe-citations 6hkr" style="background-color:#fffaf0;"></div>
== References ==
<references/>
__TOC__
</StructureSection>
[[Category: Human]]
[[Category: Chisholm, D]]
[[Category: Pohl, E]]
[[Category: Tomlinson, C]]
[[Category: Whiting, A]]
[[Category: Crabpii]]
[[Category: Dc271]]
[[Category: Fluorescent]]
[[Category: Retinoid]]
[[Category: Signaling protein]]